ClinicalTrials.gg
CompletedNCT01697696Updated Mar 16, 2016Results posted

Long Term Safety Study of NVA237 vs QAB149 in COPD Patients

A Phase 3 interventional study of NVA237 and Long-acting beta 2-agonist (LABA) in Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals. Completed at 61 sites in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2016-03-16.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
511
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
20th of 73
511 · median 152
Started
2012
with 10 others
Phase 3
33 of 73
1 open now
Registered
26th of 73
by date
Lead sponsor
19 of 73
Novartis Pharmaceuticals

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 20th largest by enrollment, is one of 11 that started in 2012, is one of 33 in phase 3, and was the 26th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • COPD, NVA237, QAB149, glycopyrronium bromide
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients with according to GOLD 2011 who have signed .
  2. Patients with airflow limitation of 30-80% post-bronchodilator at run-in.
  3. Current or ex-smokers with a smoking history of at least 10 pack years
  4. Patients with a mMRC score of at least 2 at run-in.

Exclusion criteria

Exclusion Criteria:

  1. Patients for muscarinic antagonist agents and beta-2 agonists
  2. Patients with a history of of any organ system, treated or untreated, within the last five years
  3. Patients with narrow-angle glaucoma, BPH or bladder-neck obstruction or moderate-severe renal impairment or urinary retention
  4. Patients who had a exacerbation within 6 weeks prior to screening.
  5. Patients requiring long term oxygen therapy prescribed for more than 12 hr per day.
  6. Patients with a history of asthma.
  7. Patients with an onset of respiratory symptoms, including COPD diagnosis, prior to 40 years of age.
  8. Patients with a blood eosinophil count of greater than 600 mm/3 during run-in
  9. Patients with concomitant pulmonary disease
  10. Patients with a history of certain cardiovascular co-morbid conditions
  11. Patients with a diagnosis of alpha-1 anti-trypsin deficiency
  12. Patients with active pulmonary tuberculosis
  13. Patients in the active phase of a pulmonary rehabilitation programme
  14. Other protocol-defined inclusion / exclusion criteria may apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
511 participants (actual)

Study arms

  • Experimental
    NVA237 dose 1

    NVA237 dose 1

    Drug: NVA237

  • Active comparator
    Long-acting beta 2-agonist (LABA)

    QAB149

    Drug: Long-acting beta 2-agonist (LABA) · Drug: Placebo

Interventions

  • DrugNVA237

    NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI

  • DrugLong-acting beta 2-agonist (LABA)

    QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI

  • DrugPlacebo

    Placebo to match QAB149

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate

    Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.

    Time frame: 52 weeks

Secondary outcomes

  1. Time to Treatment Discontinuation

    Discontinuation rates are calculated using the Kaplan Meier method. The protocol allowed patients to discontinue outside the treatment window, hence we have a patient who discontinued at Day 388. Reasons for discontinuing treatment are Subject/guardian decision, Adverse event, Protocol deviation Lack of efficacy, Physician decision, Dosing error, Disease improvement under study, Pregnancy, Technical problems

    Time frame: 52 Weeks

  2. Change From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 52

    Change from baseline in pre-dose trough FEV1 was analyzed using a repeated measures analysis of covariance model which contained treatment, baseline FEV1, visit, baseline smoking status, baseline ICS use, COPD severity and treatment by visit, visit by baseline FEV1 interactions. An unstructured variance-covariance error matrix was used .Pulmonary function assessments were performed using centralized spirometry according to international standards. Pre-dose trough FEV1 was defined as the mean of FEV1 at -45 min and -15 min before the morning dose at Week 52. Baseline FEV1 was defined as the mean of the pre-dose FEV1 at -45 min and -15 min on Day 1.

    Time frame: -45 min and -15 minutes baseline and at Week 52

  3. Change From Baseline in Pre-dose Forced Expiratory Volume (FEV1) in One Second at All Post Baseline Timepoints

    Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.

    Time frame: -45 min and -15 minutes baseline and at Week 52

  4. Change From Baseline in Pre-dose Forced Vital Capacity (FVC) at All Post-baseline Timepoints

    Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FVC was defined as the average of the pre-dose FVC measured at -45 minutes (min) and -15 min at day 1.

    Time frame: -45 min and -15 minutes baseline and at Week 52

  5. Change From Baseline in COPD Symptoms

    The total symptom score was defined as the sum of individual cores for respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and reathlessness. Where a patient had a morning score and an evening score for an individual symptom on one particular day then the worst score was to be taken as the daily score for that symptom. Each symptom scale ranged from 0-3 where 0 was no symptoms and 3 was the worst. The total daily/daytime/nighttime symptom score consists of looking at the score for 6 symptoms and can therefore have a minimum score of 0 or a maximum of 18.

    Time frame: 52 weeks

  6. Change From Baseline in COPD Symptoms

    Percentage of days with 'no daytime symptoms' A day with 'no daytime symptoms' was defined from the diary data as any day where the patient had recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) and no puffs of rescue medication during the past 12 hours (approximately 8 am to 8pm). However, a patient was not considered symptom free if they had used rescue medication that day even if his/her total daytime symptoms score was zero. Percentage of nights with 'no nighttime awakenings' A night with 'no nighttime awakenings' was defined from diary data as any night where the patient did not wake up due to symptoms. The total number of nights with 'no nighttime awakenings' over the treatment period was divided by the total number of nights where diary recordings had been made in order to derive the percentage nights with 'no nighttime awakenings'.

    Time frame: 52 weeks

  7. Change From Baseline in Mean Daily Number of Puffs of Rescue Medication

    The number of puffs of rescue medication taken in the previous 12 hours was recorded by the patients in the eDiary in the morning and evening. The total number of puffs of rescue medication per day over the 52 week treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator. Change from baseline in number of puffs were analyzed using a linear mixed model which contained treatment, baseline number of puffs, baseline smoking status, baseline ICS use and COPD disease severity as fixed effects with center as a random effect

    Time frame: 52 weeks

  8. Time to First COPD Exacerbation (Moderate or Severe).

    COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if hospitalizations were required. Rates are calculated using the Kaplan Meier method.

    Time frame: 52 weeks

07

Results

Posted Mar 16, 2016

Participant flow

Participant flow — Overall Study
MilestoneNVA237QAB149
Started254257
Safety set251256
Full analysis set (fas)251255
Completed207210
Not completed4747
Withdrew: Study terminated by sponsor03
Withdrew: Protocol deviation10
Withdrew: Physician decision10
Withdrew: Death42
Withdrew: Lost to follow-up107
Withdrew: Subject/guardian decision3135

Outcome measures

PrimaryPercentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate

Adverse events are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal lab finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgments of the investigators represent significant hazards.

Time frame:
52 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate
Percentage of participantsNVA237QAB149
Percentage of Participants Reporting Safety and Tolerability in Terms of Adverse Event (AE) Reporting Rate77.377
SecondaryTime to Treatment Discontinuation

Discontinuation rates are calculated using the Kaplan Meier method. The protocol allowed patients to discontinue outside the treatment window, hence we have a patient who discontinued at Day 388. Reasons for discontinuing treatment are Subject/guardian decision, Adverse event, Protocol deviation Lack of efficacy, Physician decision, Dosing error, Disease improvement under study, Pregnancy, Technical problems

Time frame:
52 Weeks
Reported as:
Median · Days
Time to Treatment Discontinuation
DaysNVA237QAB149
Time to Treatment DiscontinuationNA (NA to NA)388 (388 to NA)
SecondaryChange From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 52

Change from baseline in pre-dose trough FEV1 was analyzed using a repeated measures analysis of covariance model which contained treatment, baseline FEV1, visit, baseline smoking status, baseline ICS use, COPD severity and treatment by visit, visit by baseline FEV1 interactions. An unstructured variance-covariance error matrix was used .Pulmonary function assessments were performed using centralized spirometry according to international standards. Pre-dose trough FEV1 was defined as the mean of FEV1 at -45 min and -15 min before the morning dose at Week 52. Baseline FEV1 was defined as the mean of the pre-dose FEV1 at -45 min and -15 min on Day 1.

Time frame:
-45 min and -15 minutes baseline and at Week 52
Reported as:
Least squares mean · Liters
Change From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 52
LitersNVA237QAB149
Change From Baseline in Mean Forced Expiratory Volume (Average of the Two FEV1 Measurements 45 and 15 Minutes Pre-dose) in One Second at Week 520.056 ± 0.02110.060 ± 0.0213
SecondaryChange From Baseline in Pre-dose Forced Expiratory Volume (FEV1) in One Second at All Post Baseline Timepoints

Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FEV1 was defined as the average of the pre-dose FEV1 measured at -45 minutes (min) and -15 min at day 1.

Time frame:
-45 min and -15 minutes baseline and at Week 52
Reported as:
Mean · Liters
Change From Baseline in Pre-dose Forced Expiratory Volume (FEV1) in One Second at All Post Baseline Timepoints
LitersNVA237QAB149
Day 29/-45min0.104 ± 0.18480.118 ± 0.2093
Day 29/-15min0.123 ± 0.18720.138 ± 0.2061
Day 57/-45min0.098 ± 0.20170.101 ± 0.2091
Day 57/-15min0.120 ± 0.20250.107 ± 0.2111
Day 85/-45min0.105 ± 0.24100.085 ± 0.2255
Day 85/-15min0.111 ± 0.21370.099 ± 0.2328
Day 141/-45min0.071 ± 0.21680.089 ± 0.2595
Day 141/-15min0.096 ± 0.20600.108 ± 0.2670
Day 197/-45min0.071 ± 0.23700.082 ± 0.2637
Day 197/-15min0.073 ± 0.21500.090 ± 0.2827
Day 253/-45min0.092 ± 0.27740.087 ± 0.2679
Day 253/-15min0.094 ± 0.21000.103 ± 0.2659
Day 309/-45min0.068 ± 0.28500.094 ± 0.2594
Day 309/-15min0.088 ± 0.28450.112 ± 0.2638
Day 365/-45min0.057 ± 0.25410.088 ± 0.2521
Day 365/-15min0.087 ± 0.25920.090 ± 0.2627
SecondaryChange From Baseline in Pre-dose Forced Vital Capacity (FVC) at All Post-baseline Timepoints

Pulmonary function assessments were performed using centralized spirometry according to international standards. Baseline FVC was defined as the average of the pre-dose FVC measured at -45 minutes (min) and -15 min at day 1.

Time frame:
-45 min and -15 minutes baseline and at Week 52
Reported as:
Mean · Liters
Change From Baseline in Pre-dose Forced Vital Capacity (FVC) at All Post-baseline Timepoints
LitersNVA237QAB149
Day 29/-45min0.191 ± 0.34330.170 ± 0.3536
Day 29/-15min0.217 ± 0.34400.194 ± 0.3495
Day 57/-45min0.168 ± 0.35010.140 ± 0.3655
Day 57/-15min0.210 ± 0.34140.178 ± 0.3610
Day 85/-45min0.171 ± 0.39070.094 ± 0.3711
Day 85/-15min0.188 ± 0.38750.118 ± 0.3823
Day 141/-45min0.159 ± 0.37420.112 ± 0.3822
Day 141/-15min0.182 ± 0.37060.141 ± 0.4068
Day 197/-45min0.140 ± 0.38790.075 ± 0.4043
Day 197/-15min0.133 ± 0.39920.083 ± 0.4183
Day 253/-45min0.167 ± 0.45670.100 ± 0.4219
Day 253/-15min0.153 ± 0.37030.125 ± 0.3984
Day 309/-45min0.120 ± 0.45390.094 ± 0.4122
Day 309/-15min0.149 ± 0.44510.114 ± 0.4207
Day 365/-45min0.116 ± 0.40530.109 ± 0.4426
Day 365/-15min0.143 ± 0.39700.097 ± 0.4171
SecondaryChange From Baseline in COPD Symptoms

The total symptom score was defined as the sum of individual cores for respiratory symptoms, cough, wheeze, amount of sputum, color of sputum, and reathlessness. Where a patient had a morning score and an evening score for an individual symptom on one particular day then the worst score was to be taken as the daily score for that symptom. Each symptom scale ranged from 0-3 where 0 was no symptoms and 3 was the worst. The total daily/daytime/nighttime symptom score consists of looking at the score for 6 symptoms and can therefore have a minimum score of 0 or a maximum of 18.

Time frame:
52 weeks
Reported as:
Least squares mean · scores on a scale
Change From Baseline in COPD Symptoms
scores on a scaleNVA237QAB149
Daily total symptom score (n=231, 227)-1.18 ± 0.137-1.47 ± 0.137
Daytime total symptom score (n=221, 220)-0.95 ± 0.129-1.14 ± 0.129
Nighttime total symptom score (n=226, 222)-1.11 ± 0.126-1.25 ± 0.128
SecondaryChange From Baseline in COPD Symptoms

Percentage of days with 'no daytime symptoms' A day with 'no daytime symptoms' was defined from the diary data as any day where the patient had recorded in the evening no cough, no wheeze, no production of sputum and no feeling of breathlessness (other than when running) and no puffs of rescue medication during the past 12 hours (approximately 8 am to 8pm). However, a patient was not considered symptom free if they had used rescue medication that day even if his/her total daytime symptoms score was zero. Percentage of nights with 'no nighttime awakenings' A night with 'no nighttime awakenings' was defined from diary data as any night where the patient did not wake up due to symptoms. The total number of nights with 'no nighttime awakenings' over the treatment period was divided by the total number of nights where diary recordings had been made in order to derive the percentage nights with 'no nighttime awakenings'.

Time frame:
52 weeks
Reported as:
Least squares mean · Percentage of days / nights
Change From Baseline in COPD Symptoms
Percentage of days / nightsNVA237QAB149
Nights with no nighttime awakenings (n=226, 222)17.4 ± 1.8418.0 ± 1.86
Days with no daytime symptoms (n=221, 220)6.0 ± 1.385.1 ± 1.38
Days able to perform daily activities(n=221,220)5.4 ± 2.098.5 ± 2.10
SecondaryChange From Baseline in Mean Daily Number of Puffs of Rescue Medication

The number of puffs of rescue medication taken in the previous 12 hours was recorded by the patients in the eDiary in the morning and evening. The total number of puffs of rescue medication per day over the 52 week treatment period was calculated and divided by the total number of days with non-missing rescue data to derive the mean daily number of puffs of rescue medication taken for the patient. If the number of puffs was missing for part of the day (either morning or evening), then a half day was used in the denominator. Change from baseline in number of puffs were analyzed using a linear mixed model which contained treatment, baseline number of puffs, baseline smoking status, baseline ICS use and COPD disease severity as fixed effects with center as a random effect

Time frame:
52 weeks
Reported as:
Least squares mean · Number of puffs
Change From Baseline in Mean Daily Number of Puffs of Rescue Medication
Number of puffsNVA237QAB149
Daily (n=231, 227)-1.16 ± 0.199-1.79 ± 0.199
Daytime (n=221, 220)-0.71 ± 0.112-1.05 ± 0.112
Nighttime (n=226, 222)-0.52 ± 0.094-0.73 ± 0.095
SecondaryTime to First COPD Exacerbation (Moderate or Severe).

COPD exacerbations are considered to be moderate if treatment with systemic corticosteroids and/or antibiotics was required. COPD exacerbations are considered to be severe if hospitalizations were required. Rates are calculated using the Kaplan Meier method.

Time frame:
52 weeks
Reported as:
Median · Days
Time to First COPD Exacerbation (Moderate or Severe).
DaysNVA237QAB149
Time to First COPD Exacerbation (Moderate or Severe).NA (NA to NA)NA (NA to NA)

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NVA237—33/251 (13.1%)165/251 (65.7%)
QAB149—34/256 (13.3%)170/256 (66.4%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventNVA237QAB149
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders11/25112/256
PNEUMONIAInfections and infestations5/2514/256
RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders3/2510/256
ATRIAL FIBRILLATIONCardiac disorders2/2511/256
NON-CARDIAC CHEST PAINGeneral disorders2/2510/256
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders2/2512/256
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/2512/256
CARDIAC ARRESTCardiac disorders0/2512/256
SEPSISInfections and infestations0/2512/256
HYPONATRAEMIAMetabolism and nutrition disorders0/2512/256
Most frequent other events
Showing 10 of 68
Most frequent other events
EventNVA237QAB149
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders83/25188/256
NASOPHARYNGITISInfections and infestations20/25127/256
COUGHRespiratory, thoracic and mediastinal disorders18/25120/256
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations14/25116/256
DYSPNOEARespiratory, thoracic and mediastinal disorders13/2519/256
VIRAL UPPER RESPIRATORY TRACT INFECTIONInfections and infestations12/25112/256
SINUSITISInfections and infestations10/25112/256
FATIGUEGeneral disorders11/2513/256
BRONCHITISInfections and infestations11/2519/256
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders11/25111/256

Baseline characteristics

The Safety set included all patients that received at least one dose of study drug and had at least one-post baseline assessment . Subjects were analyzed according to the treatment they received (if a subject incorrectly took more than one treatment, the subject was analyzed according to the treatment they were randomized to).

Age, Continuous
Age, Continuous(Years)NVA237QAB149Total
Mean63.3 ± 9.1563.2 ± 8.9163.3 ± 9.02
Sex: Female, Male
Sex: Female, Male(Participants)NVA237QAB149Total
Female110107217
Male141149290
08

Study locations

61 sites
  • Novartis Investigative Site
    Gulf Shores, Alabama 36547, United States
  • Novartis Investigative Site
    Mobile, Alabama 36608, United States
  • Novartis Investigative Site
    Tucson, Arizona 85712, United States
  • Novartis Investigative Site
    Riverside, California 92506, United States
  • Novartis Investigative Site
    Fort Collins, Colorado 80528, United States
  • Novartis Investigative Site
    Wheat Ridge, Colorado 80033, United States
  • Novartis Investigative Site
    Glastonbury, Connecticut 06033, United States
  • Novartis Investigative Site
    Stamford, Connecticut 06902, United States
  • Novartis Investigative Site
    Waterbury, Connecticut 06708, United States
  • Novartis Investigative Site
    Clearwater, Florida 33765, United States
  • Novartis Investigative Site
    Hialeah, Florida 33016, United States
  • Novartis Investigative Site
    Miami, Florida 33165, United States
  • Novartis Investigative Site
    Miami, Florida 33172, United States
  • Novartis Investigative Site
    Miami, Florida 33175, United States
  • Novartis Investigative Site
    Oakland Park, Florida 33334, United States
  • Novartis Investigative Site
    Pensacola, Florida 32503, United States
  • Novartis Investigative Site
    Couer D'Alene, Idaho 83814, United States
  • Novartis Investigative Site
    Newburgh, Indiana 47630, United States
  • Novartis Investigative Site
    Topeka, Kansas 66606, United States
  • Novartis Investigative Site
    Florence, Kentucky 41042, United States
  • Novartis Investigative Site
    Madisonville, Kentucky 42431, United States
  • Novartis Investigative Site
    New Orleans, Louisiana 70119, United States
  • Novartis Investigative Site
    Opelousas, Louisiana 70570, United States
  • Novartis Investigative Site
    Biddeford, Maine 04005, United States
  • Novartis Investigative Site
    Worchester, Massachusetts 01608, United States
  • Novartis Investigative Site
    Edina, Minnesota 55435, United States
  • Novartis Investigative Site
    Fridley, Minnesota 55432, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota 55402, United States
  • Novartis Investigative Site
    Minneapolis, Minnesota 55407, United States
  • Novartis Investigative Site
    Fremont, Nebraska 68025, United States
  • Novartis Investigative Site
    Omaha, Nebraska 68134, United States
  • Novartis Investigative Site
    Henderson, Nevada 89014, United States
  • Novartis Investigative Site
    Las Vegas, Nevada 89119, United States
  • Novartis Investigative Site
    Lebanon, New Hampshire 03756, United States
  • Novartis Investigative Site
    Calabash, North Carolina 28467, United States
  • Novartis Investigative Site
    Tabor City, North Carolina 28463, United States
  • Novartis Investigative Site
    Columbus, Ohio 43215, United States
  • Novartis Investigative Site
    Columbus, Ohio 43235, United States
  • Novartis Investigative Site
    Marion, Ohio 43302, United States
  • Novartis Investigative Site
    Zanesville, Ohio 43701, United States
  • Novartis Investigative Site
    Eugene, Oregon 97404-3233, United States
  • Novartis Investigative Site
    Philadelphia, Pennsylvania 19140, United States
  • Novartis Investigative Site
    Warwick, Rhode Island 02886, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29412, United States
  • Novartis Investigative Site
    Columbia, South Carolina 29204, United States
  • Novartis Investigative Site
    Greenville, South Carolina 29605, United States
  • Novartis Investigative Site
    Greer, South Carolina 29651, United States
  • Novartis Investigative Site
    N. Myrtle Beach, South Carolina 29582, United States
  • Novartis Investigative Site
    Boerne, Texas 78006, United States
  • Novartis Investigative Site
    El Paso, Texas 79902, United States
  • Novartis Investigative Site
    Houston, Texas 77043, United States
  • Novartis Investigative Site
    Houston, Texas 77081, United States
  • Novartis Investigative Site
    Kingwood, Texas 77339, United States
  • Novartis Investigative Site
    San Antonio, Texas 78229, United States
  • Novartis Investigative Site
    White River Junction, Vermont 05009, United States
  • Novartis Investigative Site
    Burke, Virginia 22015, United States
  • Novartis Investigative Site
    Fredericksburg, Virginia 22401, United States
  • Novartis Investigative Site
    Manassas, Virginia 20110, United States
  • Novartis Investigative Site
    Richmond, Virginia 23225, United States
  • Novartis Investigative Site
    Richmond, Virginia 23229, United States
  • Novartis Investigative Site
    Oregon, Wisconsin 53575, United States
09

References and documents

Publications

  • Mahler DA, Gifford AH, Satti A, Jessop N, Eckert JH, D'Andrea P, Mota F, Banerjee R. Long-term safety of glycopyrrolate: A randomized study in patients with moderate-to-severe COPD (GEM3). Respir Med. 2016 Jun;115:39-45. doi: 10.1016/j.rmed.2016.03.015. Epub 2016 Mar 22. PubMed 27215502 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2012
First posted
Oct 2, 2012
Start
Oct 2012
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Mar 16, 2016
Last update
Mar 16, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01697696
Responsible party
Sponsor
First posted
Oct 2, 2012
Start date
Oct 2012
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Mar 16, 2016
Last update
Mar 16, 2016

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glycopyrrolate

Start the discussion